Neurobiology of Disease Spinal Cord Injury and Rege

Clinical Trials in Spinal Cord Injury-Overcome Partial Conduction Block

•K+ channel blockers

•4-Aminopyridine (4-AP; Fampridine-SR, Acorda)

•HP-184 (Sanofi-Aventis)

•Both Phase III

Na+

K+

4-AP


	4-AP dose limited by irritability, confusion and seizures. HP-184 (N-[N-propyl]-N-[3-fluoro-4-pyridinyl]-1H-3-methylindole-1-amine
	hydrochloride) is a combined K and frequency/use-dependent Na channel blocker that seems to have fewer side effects and has looked promising in phase II trials on chronic ASIA C & D patients.